Market

It is difficult to assess the market for mineral-based vaccine adjuvants in oncology. We need to distinguish between aluminum-based mineral adjuvants, used in anti-infectious vaccines against cancer-causing viruses (hepatitis B, papillomavirus). In this case, of course, their use is currently highly developed, since they concern or should concern every female individual for the latter, and everyone for the former.

In the case of therapeutic vaccines based on purified or synthesized tumor proteins, the market will depend on the therapeutic vaccine's indication. There is currently no consensus on this indication, but numerous pathologies such as osteosarcoma, lymphoma, melanoma, carcinoma, pancreatic cancer and disseminated cancers fall within their indication.

From a regulatory standpoint, adjuvants are not licensed as such. It's the vaccine...